Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema

Kaori Tenkumo, Kouki Fukuda, Ayana Yamashita, Chieko Shiragami, Hidetaka Yamaji, Fumio Shiraga

Research output: Contribution to journalArticle


To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalJapanese Journal of Clinical Ophthalmology
Issue number6
Publication statusPublished - Jun 2010
Externally publishedYes


ASJC Scopus subject areas

  • Ophthalmology

Cite this